EFFECTS OF MONOCLONAL ANTIBODY ANTIEGF RECEPTOR ON HUMAN NASOPHARYNGEAL CARCINOMA CELL AND OTHER TUMOR CELLS

Three anti-EGF receptor MoAbs were used in these studies. Administration of MoAbs 3 and 176 inhibited tumor formation in nude mice by CNE-2, a poorly differentiated nasopharyngeal carcinoma cell line and A431, an epidermoid carcinoma cell line. When the same MoAbs were used in treatment against HeLa, a cervical carcinoma, tumor growth was not affected. The number of EGF receptors and apparent dissociation constants for ~(125)I-EGF on CNE-2 and A431 was 1.3×10~(?)/cell (Kd 7.7×10~(-8)mol/L) and 1.4×10~6/cell(Kd 2.4×10~(-9)mol/L), respectively. Both MoAbs 3 and 176, capable of competing with EGF for receptor binding, showed significant tumor growth inhibition. MoAb 101 was incapable of blocking the binding of EGF to its receptor, and not as effective as MoAbs 3 and 176 in tumor growth inhibition. Our observation is that the MoAb anti-EGF receptor is cytostatic rather than cytocidal, in vitro against CNE-2 and A431.     

抗EGF受体的单克隆抗体对人鼻咽癌及其他肿瘤细胞生长的影响

本文报道三种抗EGF受体的单克隆抗体(MoAbs)用于裸鼠移植入肿瘤细胞的生长抑制研究。注射MoAbs 3和176分别抑制了低分化鼻咽癌细胞系CNE-2和上皮样癌细胞系A431的生长,而相同的抗体用于宫颈癌细胞系HeLa时,则无抑制作用.用~(125)I-EGF结合试验测定了CNE-2和A431细胞膜EGF受体的含量分别为1.3×10~5/细胞(Kd 7.7×10~(-8)mol/L),1.4×10~6/细胞(Kd 2.4×10(-9)mol/L)。实验结果亦显示MoAbs 3和176分别可竞争性地抑制EGF与其受体的结合,这两种抗体同时显示良好的抑瘤效应,而不能抑制EGF与其受体结合的MoAb101,则抑瘤效果亦差。上述MoAbs在体外有补体存在时不具备杀伤CNE-2及A431等肿瘤细胞。